Renovaro Biosciences Inc. (RENB)

NASDAQ: RENB · IEX Real-Time Price · USD

1.350

-0.050 (-3.57%)

At close: Jul 19, 2024, 4:00 PM

1.260

-0.090 (-6.67%)

Pre-market: Jul 22, 2024, 4:05 AM EDT

Renovaro Biosciences Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year Ending	TTM	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	2018 - 2017
Selling, General & Admin	22.51	15.32	14.33	7.56	7.12	8.42	Upgrade
Research & Development	3.27	4.17	8.37	15.72	4.69	2.5	Upgrade
Other Operating Expenses	27.5	19.07	93.38	0.12	0.11	0.07	Upgrade
Operating Expenses	53.28	38.56	116.08	23.4	11.92	10.99	Upgrade
Operating Income	-53.28	-38.56	-116.08	-23.4	-11.92	-10.99	Upgrade
Interest Expense / Income	0.91	0.58	0.37	0.38	0.1	0	Upgrade
Other Expense / Income	-0.26	0.55	-3.02	3.07	-0.61	7.03	Upgrade
Pretax Income	-53.93	-39.68	-113.43	-26.85	-11.42	-18.02	Upgrade
Income Tax	0	0	0	-0.13	0	0	Upgrade
Net Income	-53.93	-39.68	-113.43	-26.72	-11.42	-18.02	Upgrade
Shares Outstanding (Basic)	107	56	53	47	46	38	Upgrade
Shares Outstanding (Diluted)	107	56	53	47	46	38	Upgrade
Shares Change	92.02%	7.11%	11.37%	1.81%	23.38%	71.15%	Upgrade
EPS (Basic)	-0.78	-0.71	-2.16	-0.57	-0.25	-0.48	Upgrade
EPS (Diluted)	-0.78	-0.71	-2.16	-0.57	-0.25	-0.48	Upgrade
Free Cash Flow	-10.87	-11.8	-15.74	-20.66	-10.64	-9.22	Upgrade
Free Cash Flow Per Share	-0.10	-0.21	-0.30	-0.44	-0.23	-0.25	Upgrade
EBITDA	-52.9	-38.99	-112.94	-26.35	-10.95	-17.94	Upgrade
Depreciation & Amortization	0.12	0.11	0.12	0.12	0.37	0.07	Upgrade
EBIT	-53.02	-39.1	-113.06	-26.47	-11.31	-18.02	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).